What top creators are saying about Hims & Hers Health, Inc.(HIMS)— Page 6

The stock is seen as 'finally getting some love' as its price catches up to strong fundamentals, including an 'outstanding Q3' earnings report and 'great execution'.

Mentioned as an example of a '#1 player' in its industry, against which challenger stocks like LifeMD are compared.

The speaker views HIMS as a recession-resistant, undervalued business due to its subscription model. The investment thesis is that the market is incorrectly pricing it as a high-risk growth stock, presenting a mispriced opportunity.

The company reported an 'outstanding Q3' and management approved a $250 million share buyback, a strong signal of confidence despite the stock being down 46%.

Cited as a company with 'outstanding earnings' whose stock still fell, highlighting the negative macro pressure dominating the market over company-specific fundamentals.

Considered 'way too cheap' on an absolute basis but is much more expensive than LFMD and has lower gross margins. Its business model avoids insurance entirely, making it a pure cash-pay business, and the stock is noted to be a 'roller coaster' despite strong performance.

Despite an outstanding Q3 earnings report, the stock has sold off significantly. Management's million-share buyback program signals they believe the stock is undervalued, presenting a potential buying opportunity.

A newly announced $250 million share buyback is viewed as a positive move for the heavily shorted, fast-growing company trading at a low multiple of less than 4x sales.

The stock dropped 41% despite 'absolutely outstanding earnings,' suggesting the decline is due to broad market liquidity issues rather than company fundamentals, which could represent a buying opportunity.

The host is very bullish, viewing the recent 41% sell-off in 29 days as a compelling entry point. They believe the company has the potential to disrupt traditional doctor's visits, suggesting a much larger total addressable market.

The market is undervaluing HIMS, viewing it as a lifestyle brand rather than a broad healthcare disruptor. Its 'Hims Labs' product offers a 10x-100x cost advantage, creating a massive consumer value proposition and significant growth potential.

The recent 42% drawdown is viewed as a major buying opportunity, disconnected from strong performance. The new lab testing service is a massive potential growth driver, and the valuation is described as an 'absolute steal'.

Strategically positioning itself as a key distribution platform for the mass adoption of GLP-1 weight-loss drugs, which is viewed as a massive growth opportunity.

The speaker is extremely bullish, citing a major new product with a 300 million person TAM that aims to disrupt primary care, which the market is ignoring.

Cited as an example of a hyper-growth small-cap stock that is currently weak due to the broader market liquidity crisis affecting risky assets.

The stock's 34% decline is seen as a disconnect from strong Q3 performance. Potential catalysts include a renewed partnership with Novo Nordisk for GLP-1 drugs, new product lines for testosterone and menopause, and a 'big announcement' scheduled for November 13th.

Serves as the main industry comparable and valuation benchmark for LifeMD. The significant valuation gap between HIMS and LFMD is the core of the bullish thesis for LFMD, as Hims trades at a much higher valuation multiple.

The recent stock drop is seen as a significant buying opportunity, as it is attributed to a market-wide sell-off and is disconnected from the company's 'amazing' Q3 earnings (49% YoY revenue growth). Future catalysts include a new product reveal and potential partnerships.

The company is considered undervalued and 'very, very cheap' with outstanding Q3 results showing a strong revenue growth rebound, increasing profitability, and impressive customer metrics. The analysis suggests the stock should be valued more like a high-growth SaaS company.

The speaker is very bullish long-term, viewing the $4.00 - $4.50 price range as a cheap entry point, with key growth drivers in microdose GLP-1s, testosterone, and menopause treatments.

Mentioned as an example of a strong company whose stock was 'dumping' for no clear reason, reinforcing the view that the market is currently fearful and irrational.

Viewed as a long-term growth investment disrupting the healthcare industry. New product lines like Testosterone and Menopause treatments are expected to be huge growth drivers. Recent dips are viewed as buying opportunities.

Making a strategic long-term investment in Grail for cancer screening, positioning it as a future leader in preventative care. The stock is currently volatile and down, which the speaker views as a buying opportunity.

Described as a stock that 'trades on sentiment' more than others and is expected to be very volatile, going 'back up' and then 'back down'.

The stock was 'wrecked,' falling 16% in a single day due to negative sentiment related to the GLP-1 drug space, indicating high risk and uncertainty.

The speaker views the 21% drop in the stock price as a 'buying opportunity' based on a market overreaction, arguing that HIMS is a diversified telehealth platform and not just a GLP-1 company.

Considered very bearish due to multiple red flags: questionable insider selling by the CEO, a 'sell' rating from Bank of America, and ongoing legal/regulatory risks.

The recent 7% drop is viewed as a buying opportunity, as the market is believed to be ignoring major positive news (expansion into menopause treatment) and the company's strong growth fundamentals.

The expansion into the menopause market is seen as a significant growth driver. The host believes the company is cheap with strong growth rates, though he sold half his position for portfolio management after a large run-up.

The launch of its Menopause product line is considered a major growth catalyst, opening up an enormous and underserved addressable market. The 'Hers' business segment is projected to reach $1 billion in sales by 2026.

Considered 'too cheap' after an irrational sell-off, presenting a buying opportunity ahead of bullish catalysts like new product lines (testosterone, menopause) and international expansion. Attractive entry points are cited at $51-$53.

The speaker is bullish, viewing the nearly 10% drop as a buying opportunity. The sell-off is considered illogical as the company has a defensive subscription model and high margins, and was likely sold off due to being a small-cap stock in a market panic.

The stock was down almost 8% and is viewed as a 'buy the dip' opportunity, as its sell-off is attributed to irrational market panic ('basket selling') rather than any weakness in the business.

While included in the MEME ETF, the host believes it to be a 'legitimate growth company,' not a meme stock, implying a positive fundamental view.

The market is seen as misunderstanding the company as just a weight-loss drug seller, while it is a disruptive digital health platform with a 'still very cheap' stock and multiple growth catalysts like expansion into testosterone and menopause treatments.

The stock was down significantly, attributed to a potential 'hit piece' and news that the founder was stepping down.

The speaker is extremely bullish, viewing the recent price drop as a 'buy the dip opportunity' because the market misunderstands its integrated business model, which creates a strong competitive moat through bundled services and customization.

Mentioned as a 'channel favorite' where recent extreme intraday volatility (dropping 5% at the open before closing positive) is viewed as a potential buying opportunity.

The speaker expressed a clear intention to stay away from this stock, stating there is 'no reason to trade that thing,' indicating a bearish or avoidant stance.

Focusing on high-demand, lifestyle-oriented healthcare markets (weight loss, hair loss, sexual health, mental health) through its direct-to-consumer telehealth platform.

The speaker's proprietary trading tool suggested a short position on the stock, which he also called 'tough'.

The stock rallied 16% in two days, serving as another case study that investors need to hold positions to benefit from sudden, unpredictable price increases.

The stock's positive performance is attributed to the market positively 'digesting the news of the testosterone launch,' which is viewed as a significant and bullish catalyst for future growth.

The launch of TRT and at-home lab testing is a significant growth catalyst. The stock is considered undervalued ('super cheap') and 'highest quality in its sector', making it an attractive long-term investment despite high volatility.

Directly criticized by competitor Mark Cuban, who stated customers are 'getting ripped off,' highlighting significant competitive pressure from low-cost alternatives which could threaten its pricing power and margins.

Shows explosive growth and incredible stock performance, but its weak moat and operation in a high-risk industry (pharmaceuticals) warrant caution for long-term investors.

The investment thesis is strengthening as GLP-1 lawsuit risks fade and the company pivots to a new HRT market. The business has high recurring revenue, is cash-pay, and recession-resistant.

High volatility and short squeeze potential due to 35% short interest. Legal risks concerning GLP-1s may be overstated. A rumored testosterone product launch is a significant upcoming catalyst.

The stock rallied after a judge dismissed a lawsuit against a compounding pharmacy, which is viewed as a positive legal precedent for its business model.

The speaker is very bullish, viewing the high 34% short interest as a major miscalculation by Wall Street, creating a potential for a short squeeze. Catalysts include new treatments, international expansion, and a future generic semaglutide launch.